image
Healthcare - Biotechnology - NASDAQ - US
$ 22.3332
-2.44 %
$ 1.48 B
Market Cap
-8.3
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one CLDX stock under the worst case scenario is HIDDEN Compared to the current market price of 22.3 USD, Celldex Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one CLDX stock under the base case scenario is HIDDEN Compared to the current market price of 22.3 USD, Celldex Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one CLDX stock under the best case scenario is HIDDEN Compared to the current market price of 22.3 USD, Celldex Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CLDX

image
$26.0$26.0$24.0$24.0$22.0$22.0$20.0$20.0$18.0$18.0$16.0$16.0$14.0$14.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
7.02 M REVENUE
1.99%
-195 M OPERATING INCOME
-26.23%
-158 M NET INCOME
-11.62%
-158 M OPERATING CASH FLOW
-47.06%
-290 M INVESTING CASH FLOW
-174.27%
441 M FINANCING CASH FLOW
102.07%
695 K REVENUE
-40.85%
-62.7 M OPERATING INCOME
-11.98%
-53.8 M NET INCOME
-14.24%
-54.4 M OPERATING CASH FLOW
-67.42%
43 M INVESTING CASH FLOW
78.61%
202 K FINANCING CASH FLOW
-47.67%
Balance Sheet Celldex Therapeutics, Inc.
image
Current Assets 747 M
Cash & Short-Term Investments 725 M
Receivables 700 K
Other Current Assets 21.2 M
Non-Current Assets 45.2 M
Long-Term Investments 0
PP&E 8.24 M
Other Non-Current Assets 36.9 M
91.54 %4.66 %Total Assets$792.3m
Current Liabilities 39.5 M
Accounts Payable 3.26 M
Short-Term Debt 1.45 M
Other Current Liabilities 34.8 M
Non-Current Liabilities 5.83 M
Long-Term Debt 2.36 M
Other Non-Current Liabilities 3.47 M
7.20 %3.20 %76.73 %5.21 %7.66 %Total Liabilities$45.3m
EFFICIENCY
Earnings Waterfall Celldex Therapeutics, Inc.
image
Revenue 7.02 M
Cost Of Revenue 0
Gross Profit 7.02 M
Operating Expenses 202 M
Operating Income -195 M
Other Expenses -37.2 M
Net Income -158 M
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)7m07m(202m)(195m)37m(158m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-2778.89% OPERATING MARGIN
-2778.89%
-2248.76% NET MARGIN
-2248.76%
-21.13% ROE
-21.13%
-19.92% ROA
-19.92%
-25.86% ROIC
-25.86%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Celldex Therapeutics, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -158 M
Depreciation & Amortization -12.6 M
Capital Expenditures -1.92 M
Stock-Based Compensation 34.2 M
Change in Working Capital -21.6 M
Others -23.5 M
Free Cash Flow -160 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Celldex Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for CLDX of $56.7 , with forecasts ranging from a low of $44 to a high of $80 .
CLDX Lowest Price Target Wall Street Target
44 USD 97.02%
CLDX Average Price Target Wall Street Target
56.7 USD 153.73%
CLDX Highest Price Target Wall Street Target
80 USD 258.21%
Price
Max Price Target
Min Price Target
Average Price Target
80807070606050504040303020201010Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Celldex Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
308 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company's Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1. globenewswire.com - 1 month ago
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival. globenewswire.com - 1 month ago
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress HAMPTON, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that data from the Company's Phase 2 study of barzolvolimab in chronic spontaneous urticaria will be presented at the EAACI Congress 2025 being held in Glasgow, Scotland. globenewswire.com - 1 month ago
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company's Board of Directors. globenewswire.com - 1 month ago
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.56 per share a year ago. zacks.com - 2 months ago
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update HAMPTON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2025 and provided a corporate update. globenewswire.com - 2 months ago
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company's ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). globenewswire.com - 2 months ago
Celldex Therapeutics to Present at Upcoming Investor Conferences HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: globenewswire.com - 4 months ago
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 - CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin - - Phase 1 study in healthy volunteers ongoing - globenewswire.com - 4 months ago
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025 - Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU - - 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at Week 52 - - 60% of CIndU patients reported that symptoms no longer had an impact on their quality of life at Week 12 - globenewswire.com - 4 months ago
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.57 per share a year ago. zacks.com - 5 months ago
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update HAMPTON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2024 and provided a corporate update. globenewswire.com - 5 months ago
8. Profile Summary

Celldex Therapeutics, Inc. CLDX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 1.48 B
Dividend Yield 0.00%
Description Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Contact Perryville III Building, Hampton, NJ, 08827 https://www.celldex.com
IPO Date May 15, 1986
Employees 186
Officers Prof. Joseph P. Schlessinger Ph.D. Co-Founder & Member of Scientific Advisory Board Ms. Sarah Cavanaugh Senior Vice President of Corporate Affairs & Administration Dr. Margo Heath-Chiozzi M.D. Senior Vice President of Regulatory Affairs Mr. Anthony S. Marucci M.B.A. Founder, President, Chief Executive Officer & Director Dr. Richard M. Wright Ph.D. Chief Commercial Officer & Senior Vice President Mr. Sam Martin CPA Senior Vice President, Chief Financial Officer, Secretary & Treasurer Dr. Ronald A. Pepin Ph.D. Chief Business Officer & Senior Vice President Dr. Tibor Keler Ph.D. Founder, Chief Scientific Officer & Executive Vice President Mr. Freddy A. Jimenez Esq. Senior Vice President & General Counsel Ms. Elizabeth Crowley Chief Product Development Officer & Senior Vice President